

In view of the completionof transfer of pharmaceutical formulations business to the Company's wholly ownedsubsidiary Panacea Biotec Pharma Limited ("PBPL") with effect from February 012020 the financial results of the pharma business upto Januthat wereconsidered as disposal group were presented as discontinued operations in the StandaloneFinancial Statements of the Company for financial year 2019-20 in accordance with theapplicable accounting standards. In viewof the completion of demerger of real estate undertaking including investment in RadhikaHeights Limited into the Company's then wholly owned subsidiary Ravinder Heights Limited("RVHL") with effect from Septemthe financial results of the saidreal estate undertaking for the financial year 2019-20 and for the period from April 012020 to Septemthat is considered as disposal group has been presented asdiscontinued operations in the Standalone and Consolidated Financial Statements of theCompany in accordance with the applicable accounting standards.

* Previous year's figures have been re-grouped re-classified and/or restatedwherever necessaryĭuring the year ended Mayour Company has registered revenue fromcontinuing and discontinued operations of Rs.3435.55 million as against Rs.4896.78million during the previous financial year from continuing and discontinued operations.Further Panacea Biotec as a Group has registered consolidated revenue from operations ofRs.6248.05 million as against Rs.5440.62 million during previous financial year. # Include figures for the discontinued operations

Profit / (Loss) before exceptional items and tax Profit / (Loss) before Interest Tax Depreciation & Amortization (EBITDA) The highlights of standalone and consolidated financial results of the Company are asunder: Your Directors feel pleasure in presenting the 37 th Annual Report on thebusiness and operations of the Company together with the Audited Standalone andConsolidated Financial Statements and the Auditors' Reports thereon for the financial yearended March 31 2021.
